Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

16-06-2020 | ADA 2020 | Conference coverage | Video

Researcher comment: The VERTIS-CV trial

Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

Related content

10-11-2018 | SGLT2 inhibitors | At a glance | Article

Round-up of the SGLT2 inhibitor CV outcome trials

31-01-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

10-11-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

14-06-2017 | Canagliflozin | ADA 2017 | News

Integrated CANVAS: canagliflozin offers cardioprotection at amputation cost

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits